CAS: 779-27-1; 7-Hydroxy-2-Oxo-2H-Chromene-3-Carboxylic Acid

上下游产品

malonic acid 2,4-Dihydroxybenzaldehyde 7-hydroxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester cycl-isopropylidene malonate 7-acetyloxychromone-3-carboxylic acid 7-hydroxy-2H-chromen-2-one Acetic acid (2S,3R,4S,5S,6R)-4,5-diacetoxy-6-acetoxymethyl-2-(4-{2-[4-(7-acetoxy-2-oxo-2H-chromene-3-carbonyl)-piperazin-1-yl]-1-fluoro-2-oxo-ethyl}-phenoxy)-tetrahydro-pyran-3-yl ester acetic acid 4,5-diacetoxy-2-acetoxymethyl-6-(4-{2-[4-(7-acetoxy-2-oxo-2H-chromene-3-carbonyl)piperazin-1-yl]-1-hydroxy-2-oxoethyl}phenoxy)tetrahydropyran-3-yl ester

专利信息

专利号:US-2014350235-A1
优先权日:2013-05-23
标题:In situ oligonucleotide synthesis on a paramagnetic support
发明人：AKHRAS MICHAEL S; JENSEN MICHAEL A
权利人:AKHRAS MICHAEL S; JENSEN MICHAEL A; UNIV LELAND STANFORD JUNIOR
摘要:A novel method for attaching oligonucleotides to a paramagnetic solid support is disclosed. Conventional methods of attachment require that oligonucleotides be pre-synthesized with specific end modifications, which is laborious and expensive. Instead, we attached oligonucleotides to paramagnetic beads by direct synthesis of the oligonucleotides on the surface of the beads. An external magnet was used to hold the paramagnetic beads in place during solid-phase synthesis. A magnetic force was applied directly to the beads to prevent their loss, in particular, during reagent purge-to-waste steps that involved high-pressure drain or vacuum. This method can be adapted for use in any laboratory working with conventional synthesis automation, and can be employed, for example, with single columns and multi-well titer plates.

专利号:US-7718578-B2
优先权日:2003-03-31
标 题 :Method of synthesis and testing of combinatorial libraries using microcapsules
发明人：GRIFFITHS ANDREW DAVID; ABELL CHRIS; HOLLFELDER FLORIAN; MASTROBATTISTA ENRICO
权利人:MEDICAL RES COUNCIL
摘要:The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalizing two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets. The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalized into the microcapsules.

专利号:US-10561681-B2
优先权日:2016-07-21
标题 :Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents
发明人：ARSENJANS PAVELS; VASILJEVA JELENA; DOMRACHEVA ILONA; SHESTAKOVA IRINA; KALVINS IVARS
权利人:LATVIAN INST ORGANIC SYNTHESIS
摘要:The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances.

专利号:US-5419966-A
优先权日:1991-06-10
标 题 :Solid support for synthesis of 3'-tailed oligonucleotides
发明人：REED MICHAEL W; MEYER JR RICH B; PETRIE CHARLES R; TABONE JOHN C
权利人:MICROPROBE CORP
摘要:A solid support for oligonucleotide synthesis has the structure where CPG represents a controlled pore glass matrix, the wavy line represents a carbon chain covalently linking the NH group with the controlled pore glass matrix, X is 2,2'-dimethoxytrityl or H, and R is alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl. The dimethoxytrityl group is removed from the solid support by treatment with acid, and the oligonucleotide is built, step-by-step in a conventional synthesizer after attachment of the 3' end of the first oligonucleotide unit to the hydroxyl function connected to the R group.

专利号:US-2023366125-A1
优先权日:2003-03-31
标 题:Compartmentalised combinatorial chemistry by microfluidic control
发明人：GRIFFITHS ANDREW DAVID; WEITZ DAVID A; LINK DARREN ROY; AHN KEUNHO; BIBETTE JEROME
权利人:HARVARD COLLEGE; RES & INNOVATION UK
摘要:The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.

专利号:US-6025477-A
优先权日:1986-03-31
标题 :Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
发明人：CALENOFF EMANUEL
摘要:This invention provides purified antigens which are indicative of the presence of atherosclerotic plaque. Different concentrations of these antigens have been found to coincide with the progression of atherosclerosis. The subject invention also provides different hybridoma cell lines which produce monoclonal antibodies directed to antigens associated with atherosclerosis and a hybridoma cell line which produces monoclonal antibodies directed to antigen associated with normal artery and not with plaque. The atherosclerotic plaque antigen, and monoclonal antibodies made thereto, are used in various methods for detecting in a biological sample an antigen present in, and indicative of the presence of, atherosclerotic plaque. The monoclonal antibodies are also used in methods of imaging atherosclerotic plaque, and treating atherosclerosis. The methods of treating atherosclerosis include a method of digesting atherosclerotic plaque with enzymes, and a method of ablating atherosclerotic plaque using radiation. The subject invention also provides a method of treating atherosclerotic plaque by directly delivering a drug to the plaque. The subject invention further provides a method for treating atherosclerosis by blocking the synthesis of atherosclerotic plaque or by blocking binding of antibodies to the antigen.